Recent advances of dual FGFR inhibitors as a novel therapy for cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recent advances of dual FGFR inhibitors as a novel therapy for cancer

Published:2021-03 Issue: Volume:214 Page:113205
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Liang Qi,Wang Juelan,Zhao Liyun,Hou Jun,Hu Yonghe,Shi Jianyou

Funder

Sichuan Provincial Administration of Traditional Chinese Medicine

Department of Science and Technology of Sichuan Province

Health and Family Planning Commission of Sichuan Province

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference112 articles.

1. Advances and challenges in targeting FGFR signalling in cancer;Babina;Nat. Rev. Canc.,2017

2. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors;Dienstmann;Ann. Oncol.,2014

3. FGFR a promising druggable target in cancer: molecular biology and new drugs;Porta;Crit. Rev. Oncol. Hematol.,2017

4. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders;van Rhijn;Eur. J. Hum. Genet.,2002

5. Emerging protein kinase inhibitors for the treatment of multiple myeloma;Lind;Expet Opin. Emerg. Drugs,2019

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies;Bioorganic Chemistry;2024-11

2. Chitosan and Its Derivative-Based Nanoparticles in Gastrointestinal Cancers: Molecular Mechanisms of Action and Promising Anticancer Strategies;Journal of Clinical Pharmacy and Therapeutics;2024-04-05

3. An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits;iScience;2024-04

4. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality;Acta Pharmaceutica;2024-03-01

5. Revolutionizing Wound Healing: Exploring Scarless Solutions through Drug Delivery Innovations;Molecular Pharmaceutics;2024-01-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3